U.S. pharma giant copyright scrapped two experimental weight loss tablets last year—a the moment-every day tablet, lotiglipron, due to elevated liver enzymes as well as a two times-each day tablet, danuglipron, due to solid Unwanted side effects—but CEO Albert Bourla has said the com